$-2.13 EPS Expected for GW Pharmaceuticals plc (GWPH) as of May, 8

April 16, 2018 - By Sonya McDaniel

GW Pharmaceuticals plc (NASDAQ:GWPH) is awaited to reveal earnings on May, 8., according to Zacks. This year’s earnings per share analyst estimate is awaited to be $-2.13. That is 25.29 % down compareed to $-1.7 earnings per share for last year. After $-2.43 earnings per share was announced last quarter, analysts now see EPS growth of -12.35 % for GW Pharmaceuticals plc. Its shares touched $120.58 on during the last trading session after 2.72% change.GW Pharmaceuticals plc is downtrending after having declined 9.18% since April 17, 2017. GWPH has 559,310 volume or 45.55% up from normal. GWPH underperformed by 20.73% the S&P 500.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

In total 5 analysts cover GW Pharma (NASDAQ:GWPH). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 9 are the (NASDAQ:GWPH)’s analyst reports since October 26, 2017 according to StockzIntelligence Inc. On Tuesday, February 6 the stock has “Outperform” rating by Leerink Swann. On Thursday, October 26 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Cowen & Co. On Thursday, December 14 Goldman Sachs upgraded GW Pharmaceuticals plc (NASDAQ:GWPH) rating. Goldman Sachs has “Buy” rating and $174.0 target. On Tuesday, February 6 the rating was maintained by Bank of America with “Buy”. The company rating was maintained by Leerink Swann on Thursday, December 28. In Monday, December 4 report Cantor Fitzgerald maintained it with “Buy” rating and $208.0 target. On Tuesday, January 23 the company was maintained by Leerink Swann. In Tuesday, November 14 report Bank of America maintained the stock with “Buy” rating. On Monday, February 5 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Cantor Fitzgerald.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The firm is valued at $3.40 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Currently it has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.